Levocetirizine dihydrochloride is the active chiral form of cetirizine, widely prescribed for persistent allergic rhinitis and chronic urticaria. Yiling Pharmaceutical Inc. produces this ingredient under rigorous quality standards aligned with international regulatory expectations, including cGMP compliance and robust validation practices.
As an FDA-registered facility, Yiling Pharmaceutical Inc. supports global markets with consistent supply, stability data, and documentation packages that meet stringent import requirements for levocetirizine dihydrochloride. This framework ensures reproducible purity, reliable batch performance, and traceable accountability from synthesis to release testing.
| Parameter | Specification | Test Method | Pass/Fail Criteria |
|---|---|---|---|
| Identity | Levocetirizine dihydrochloride | FTIR & NMR comparison | Match to reference standard |
| Purity (Assay) | 98.0–102.0% | HPLC with UV detection | Within limits |
| Impurities | Individual & total impurity limits | HPLC with system suitability | Compliance with ICH thresholds |
| Residual Solvents | Meets ICH Q3C(R6) | GC with FID detection | Within specified ppm |
Manufacturing Process and Quality Control at Yiling Pharmaceutical Inc
Process Validation and cGMP Compliance
Yiling Pharmaceutical Inc operates validated synthetic routes for levocetirizine dihydrochloride, emphasizing process robustness, in-process controls, and documented deviations. Calibration records, equipment maintenance logs, and environmental monitoring support consistent critical quality attributes for API batches.
Analytical Testing and Stability Programs
Comprehensive stability studies under ICH Q1A(R2) conditions define retest periods, temperature/humidity ranges, and photolytic behavior. Forced degradation studies inform method robustness, while continual method validation ensures assay and impurity remain within predetermined acceptance criteria.
Regulatory Status and FDA Clearance
DMF Filing and Regulatory Submissions
Yiling Pharmaceutical Inc maintains active Drug Master File references for levocetirizine dihydrochloride, enabling seamless integration into clients' regulatory dossiers. Consistent early audit outcomes reflect adherence to 21 CFR Part 11, ALCOA+ data integrity principles, and timely response to regulatory queries.
Global Supply Chain and Documentation
Clear Certificates of Analysis, full characterization data, and stability-indicating methods accompany each shipment. Yiling supports drug registration applications worldwide with tailored documentation, ensuring smooth customs clearance and regulatory acceptance in diverse jurisdictions.
Clinical Relevance and Patient Outcomes
Pharmacology and Efficacy Profile
As a selective peripheral histamine H1 antagonist, levocetirizine dihydrochloride exhibits a favorable balance of efficacy and tolerability. In pivotal trials, it significantly reduced nasal congestion, sneezing, and pruritus, while demonstrating a predictable safety profile across age groups.
Safety, Dosing, and Special Populations
Renal and hepatic impairment may influence exposure; hence labeling includes guidance on dose adjustments. Monitoring for somnoloness, particularly when co-administered with CNS depressants, forms part of risk minimization strategies advised in product information.
Market Position and Competitive Landscape
Cost-Effectiveness and Formulary Inclusion
With established bioequivalence to innovator products, levocetirizine dihydrochloride from Yiling Pharmaceutical Inc offers payers and providers a high-value option. Consistent supply, competitive pricing, and robust regulatory compliance contribute to formulary retention and preferred status.
Sustainability and Continuous Improvement
Investment in green chemistry principles, waste minimization, and energy-efficient processing underscores environmental stewardship. Ongoing technology transfer and process optimization align with global sustainability targets while safeguarding product quality.
Key Takeaways for Stakeholders
- Yiling Pharmaceutical Inc supplies high-purity levocetirizine dihydrochloride with validated processes and robust quality controls.
- Active FDA-registered status and comprehensive DMF documentation streamline regulatory approvals globally.
- The API delivers consistent performance, supported by stability data and clear labeling for safe use in diverse patient populations.
- Ongoing investments in process optimization and sustainability improve reliability while reducing environmental impact.
- Transparent communication, timely responses to queries, and detailed documentation ensure seamless integration into clients' supply chains.
FAQ
Reader questions
Does Yiling Pharmaceutical Inc levocetirizine dihydrochloride meet FDA current good manufacturing practice requirements?
Yes, the facility follows cGMP, maintains validation records, and complies with 21 CFR requirements, ensuring consistent quality and traceability for levocetirizine dihydrochloride API.
What documentation is provided with levocetirizine dihydrochloride API from Yiling Pharmaceutical Inc?
Each batch includes a Certificate of Analysis, stability data, impurity profiles, residue solvent reports, and full characterization data to support regulatory submissions and quality reviews.
Can levocetirizine dihydrochloride from Yiling be used in pediatric and geriatric populations?
Yes, appropriate dosing adjustments based on age, weight, and renal function are recommended; refer to official prescribing information and consult healthcare professionals for individual cases.
How does Yiling Pharmaceutical Inc ensure stability and shelf life of levocetirizine dihydrochloride?
Through rigorous stability studies under ICH conditions, defined retest periods, and controlled storage specifications, ensuring potency and impurity within acceptance criteria throughout the labeled shelf life.